Transfusion-related acute lung injury (TRALI)
is a form of acute respiratory distress syndrome (ARDS) wherein an
acute lung injury (ALI) occurs within 6 hours of blood transfusion
in a patient with no preexisting ALI prior to transfusion and has no
temporal relationship to other causes of ALI [1]. It occurs at a
frequency of 1 in 5000 units of blood products transfused and can
occur with any blood component [2]. It has been reported more
commonly in pediatric patients receiving blood transfusions for
chronic anemia [3]. Pediatric patients undergoing treatment for
acute leukemia receive frequent blood product transfusions and are
likely to be at recurrent risk of TRALI; however, literature for the
same is sparse in pediatric hematological malignancies.
Case Report
A 14-year old girl with B-precursor acute
lymphoblastic leukemia (ALL) in complete remission was receiving
consolidation chemotherapy. She initially received one bag of
platelet rich plasma followed by one bag of group specific and
cross-matched packed red blood cell transfusion. Prior to the
transfusions, she was asymptomatic and her complete blood count was
hemoglobin 7.6 g/dL, white blood cell count 2870/dL, absolute
neutrophil count 410/dL and platelets 87000/dL. The platelet
transfusion was planned two days prior to the PRBC transfusion due
to low platelet counts; the patient, however, missed her appointment
for platelet transfusion and received platelet transfusion
inadvertently along with PRBC even though her platelet counts had
improved by then. Just after completion of the PRBC transfusion, she
developed acute respiratory distress and circulatory shock
manifesting as tachypnea, tachycardia, hypoxia in room air and
hypotension. Arterial blood gas analysis revealed PaO2/FiO2 of 125
mm Hg. She required resuscitation with intravenous normal saline
fluid boluses and dopamine infusion. Intravenous hydrocortisone and
intramuscular adrenaline was administered for a possible diagnosis
of anaphylaxis. She responded to initial resuscitative measures with
stabilization of blood pressure in 2 hours and partial improvement
in respiratory distress. She also developed fever 1 hour after onset
of symptoms, and a diagnosis of septic shock was also considered.
She was empirically started on intravenous antibiotic combination of
cefperazone-sulbactam and amikacin. The patient did not have
clinical features of congestive cardiac failure. Chest radiograph
performed an hour after onset of symptoms showed bilateral diffuse
fluffy infiltrates with no cardiomegaly; chest high resolution
computed tomography (HRCT) scan done 12 hours later showed diffuse
symmetrical ground glass opacities in both lungs consistent with
diffuse alveolar damage. Since the patient had recently received
high dose steroids as part of consolidation chemotherapy for ALL,
and the respiratory distress was out of proportion to the chest
signs on auscultation as also the radiologists’ opinion of a
possible Pneumocystis carinii pneumonia (PCP) prompted the
empiric initiation of intravenous trimethoprim and sulfamethoxazole
and oral prednisolone. The respiratory distress and chest radiograph
findings normalized within 48 hours. Dopamine along with oxygen was
tapered and stopped after 3 days. The antibiotics were stopped after
3 days as the patient had become afebrile and the blood cultures
were sterile. The patient was discharged in a stable condition on
4th day of admission. There was no clinical or laboratory evidence
of miss-match transfusion or transfusion associated acute hemolysis.
She has no residual sequelae, tolerated further blood product
transfusions with no adverse event, and is currently receiving
maintenance chemotherapy. In retrospect, a diagnosis of TRALI was
considered as the most likely etiology for ARDS in our patient, as
it was temporally associated with blood transfusion and other
possible causes of ARDS in the patient were excluded. However, we
did not have any donor samples to analyze for antibodies against
recipient human leucocyte antigen (HLA) or human neutrophil antigen
(HNA). The donors (both males) were advised not to voluntarily
donate blood in future. However, they declined to provide further
samples for testing.
Discussion
TRALI is an important cause of
transfusion-related mortality [1] and appears to be a great mimicker
of a variety of conditions. The differential diagnosis of sudden
onset respiratory distress in such a setting includes infections,
pulmonary embolism, pneumothorax, congestive cardiac failure, fluid
overload, leucostasis, pulmonary hemorrhage, and anaphylactic
reactions. TRALI is a diagnosis of exclusion and based on clinical
criteria. The diagnosis of anaphylaxis, septic shock and PCP
pneumonia was considered initially in our patient and the
possibility of TRALI in our patient was only considered after 48
hours of onset of symptoms. There are few case reports of TRALI in
patients undergoing treatment for hematological malignancies
including stem cell transplantation [4-7]. There have been two case
reports of TRALI in the Indian literature in a patient with aplastic
anemia and road traffic accident, respectively [8, 9]. Both these
patients required intubation and mechanical ventilation unlike our
case.
Immune (performed antibodies) and non-immune
mechanisms (products in stored blood) have been suggested as
causative factors for TRALI, although both these mechanisms are not
mutually exclusive [1]. Laboratory demonstration of donor-recipient
antibody-antigen incompatibility in TRALI patients has been shown in
various studies to range from 25%-73% [6]. Interestingly, control
donors with no history of TRALI with their blood have also
demonstrated anti-HLA or anti-HNA antibodies, suggesting that
susceptible host factors are also needed for this entity [6]. No
donor sample may be available after a transfusion to identify the
HLA and HNA antibodies, as was in our case and in such a situation
the diagnosis of TRALI is based only on clinical and radiological
findings. Recent evidence suggests that a ‘two-hit’ process might be
responsible for TRALI implicating a non-immune pathogenesis [2].
Infections or other inflammatory triggers accounts for the first hit
wherein there is chemokine release, upregulation of adhesion
molecules and endothelial cell activation leading to neutrophil
sequestration in the lungs. The first hit occurs in the host prior
to the transfusion. In the second hit, there is amplification of the
above primed pathway by the products in the transfused blood.
Management of TRALI is supportive with major emphasis on respiratory
care [8]. Complete recovery from TRALI, both clinically and
radiologically without any permanent sequale is expected to occur in
3 to 4 days unlike other causes of ARDS. Currently there are no
mechanisms to prevent TRALI as no laboratory test can identify
patients who are likely to get TRALI [2]. Respiratory distress after
transfusion can be due to other causes like transfusion associated
circulatory overload, dyspnea and allergy [10]. However, the
temporal association of this symptom complex after blood transfusion
with supportive radiological findings and clinical course suggest a
diagnosis of TRALI.
Contributors: All authors contributed to case
management and drafting of the manuscript.
Funding: None; Competing interests:
None stated.
References
1. Toy P, Popovsky MA, Abraham E, Ambruso DR,
Holness LG, Kopko PM, et al. National Heart, Lung and Blood
Institute Working Group on TRALI. Transfusion-related acute lung
injury: definition and review. Crit Care Med. 2005;33:721-6.
2. Silliman CC, Fung YL, Ball JB, Khan SY.
Transfusion-related acute lung injury (TRALI): current concepts and
misconceptions. Blood Rev. 2009;23:245-55.
3. Sanchez R, Toy P. Transfusion related acute
lung injury: a pediatric perspective. Pediatr Blood Cancer.
2005;45:248-55.
4. Yui Y, Umeda K, Kaku H, Arai M, Hiramatsu H,
Watanabe K, et al. A pediatric case of transfusion-related
acute lung injury following bone marrow infusion. Pediatr
Transplant. 2007;11:543-6.
5. Fung YL, Williams BA. TRALI in two cases of
leukemia. J Pediatr Hematol Oncol. 2006;28:391-4.
6. Silliman CC, Boshkov LK, Mehdizadehkashi Z,
Elzi DJ, Dickey WO, Podlosky L, et al. Transfusion-related
acute lung injury: epidemiology and a prospective analysis of
etiologic factors. Blood. 2003;101:454-62.
7. Leach M, Vora AJ, Jones DA, Lucas G.
Transfusion-related acute lung injury (TRALI) following autologous
stem cell transplant for relapsed acute myeloid leukaemia: a case
report and review of the literature. Transfus Med. 1998;8:333-7.
8. Barrett NA, Kam PC. Transfusion-related acute
lung injury: a literature review. Anaesthesia. 2006;6:777-85.
9. Ilango G, Senthilkumar S, Sambanthan N. TRALI
in perioperative period-A case report. Indian J Anaesth.
2009;53:209-13.
10. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J,
Blajchman MA. TRALI Consensus Panel. Proceedings of a consensus
conference: towards an understanding of TRALI. Transfus Med Rev.
2005;19:2-31.
|